Diazepam	fluvoxamine maleate	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	42355	D003975	D016666
Diazepam	fluvoxamine maleate	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	42355	D003975	D016666
Diazepam	Fluvoxamine	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	none	D003975	none
Diazepam	Fluvoxamine	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	none	D003975	none
Diazepam	Fluvoxamine	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	none	D003975	none
Diazepam	Fluvoxamine	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	none	D003975	none
Diazepam	Alprazolam	16	15	false	none	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	596	D003975	D000525
Diazepam	Alprazolam	16	15	false	none	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	596	D003975	D000525
Diazepam	Benzodiazepines	16	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	none	D003975	D001569
Diazepam	Benzodiazepines	16	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	none	D003975	D001569
Diazepam	fluvoxamine	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	42355	D003975	D016666
Diazepam	fluvoxamine	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	42355	D003975	D016666
Diazepam	fluvoxamine	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	42355	D003975	D016666
Diazepam	fluvoxamine	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	42355	D003975	D016666
Diazepam	Lorazepam	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	6470	D003975	D008140
Diazepam	Lorazepam	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	6470	D003975	D008140
Diazepam	Lorazepam	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	6470	D003975	D008140
Diazepam	Lorazepam	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	6470	D003975	D008140
Diazepam	alprazolam	16	15	false	none	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	596	D003975	D000525
Diazepam	alprazolam	16	15	false	none	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	596	D003975	D000525
Diazepam	lorazepam	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	6470	D003975	D008140
Diazepam	lorazepam	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		3322	6470	D003975	D008140
Diazepam	lorazepam	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	6470	D003975	D008140
Diazepam	lorazepam	16	18	false	none	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		3322	6470	D003975	D008140
Diazepam	benzodiazepines	16	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	none	D003975	D001569
Diazepam	benzodiazepines	16	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  		3322	none	D003975	D001569
Sumatriptan	fluvoxamine maleate	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine maleate	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	42355	D018170	D016666
Sumatriptan	paroxetine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	32937	D018170	D017374
Sumatriptan	paroxetine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	32937	D018170	D017374
Sumatriptan	paroxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	32937	D018170	D017374
Sumatriptan	paroxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	32937	D018170	D017374
Sumatriptan	Fluvoxamine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	none	D018170	none
Sumatriptan	Fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	none	D018170	none
Sumatriptan	sumatriptan	38	38	true	negative	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		D018170	D018170
Sumatriptan	sumatriptan	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		D018170	D018170
Sumatriptan	sumatriptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		D018170	D018170
Sumatriptan	sumatriptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		D018170	D018170
Sumatriptan	sertraline	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
Sumatriptan	sertraline	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
Sumatriptan	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
Sumatriptan	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
Sumatriptan	fluvoxamine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	42355	D018170	D016666
Sumatriptan	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	42355	D018170	D016666
Sumatriptan	Tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	Tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
Sumatriptan	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
Sumatriptan	fluoxetine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
Sumatriptan	fluoxetine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
Sumatriptan	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
Sumatriptan	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
Sumatriptan	serotonin	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
Sumatriptan	serotonin	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
Sumatriptan	serotonin	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
Sumatriptan	serotonin	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
Sumatriptan	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	1311214	D018170	D012701
Sumatriptan	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	1311214	D018170	D012701
Sumatriptan	tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
Sumatriptan	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
Sumatriptan	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
Sumatriptan	triptan	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	triptan	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	triptan	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	triptan	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	triptan	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	triptan	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	triptan	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	triptan	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
Sumatriptan	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
Sumatriptan	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
fluvoxamine maleate	Methadone	24	25	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		42355	6813	D016666	D008691
fluvoxamine maleate	Methadone	24	25	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		42355	6813	D016666	D008691
fluvoxamine maleate	paroxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	32937	D016666	D017374
fluvoxamine maleate	paroxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	32937	D016666	D017374
fluvoxamine maleate	Fluvoxamine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	34	35	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	34	35	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	35	35	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	35	35	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	43	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	43	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	43	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	43	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	12	12	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	12	12	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	51	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	51	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	50	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	50	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	21	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	21	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	20	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	19	20	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	50	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	50	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	23	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	21	23	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	24	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	24	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	24	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	24	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	56	55	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	56	55	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	56	56	false	none	7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	Fluvoxamine	56	56	false	none	7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	Warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	Warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	57258	D016666	C023754
fluvoxamine maleate	tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	57258	D016666	C023754
fluvoxamine maleate	tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	57258	D016666	C023754
fluvoxamine maleate	tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	57258	D016666	C023754
fluvoxamine maleate	Alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	596	D016666	D000525
fluvoxamine maleate	Alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	596	D016666	D000525
fluvoxamine maleate	Digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	Digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	85248	D016666	C090840
fluvoxamine maleate	Alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	85248	D016666	C090840
fluvoxamine maleate	Alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	85248	D016666	C090840
fluvoxamine maleate	Alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	85248	D016666	C090840
fluvoxamine maleate	Alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	85248	D016666	C090840
fluvoxamine maleate	Alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	85248	D016666	C090840
fluvoxamine maleate	theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	10438	D016666	D013806
fluvoxamine maleate	theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	10438	D016666	D013806
fluvoxamine maleate	theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		42355	10438	D016666	D013806
fluvoxamine maleate	theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		42355	10438	D016666	D013806
fluvoxamine maleate	ketoconazole	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	6135	D016666	D007654
fluvoxamine maleate	ketoconazole	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	6135	D016666	D007654
fluvoxamine maleate	propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	8787	D016666	D011433
fluvoxamine maleate	propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	8787	D016666	D011433
fluvoxamine maleate	Mexiletine	43	45	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine maleate	Mexiletine	43	45	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine maleate	Mexiletine	46	45	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Mexiletine	46	45	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Mexiletine	44	45	false	none	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine maleate	Mexiletine	44	45	false	none	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine maleate	Aspirin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	Aspirin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	none	D016666	none
fluvoxamine maleate	sumatriptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	37418	D016666	D018170
fluvoxamine maleate	sumatriptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	37418	D016666	D018170
fluvoxamine maleate	sertraline	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	36437	D016666	D020280
fluvoxamine maleate	sertraline	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	36437	D016666	D020280
fluvoxamine maleate	alcohol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	19	20	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	19	20	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	alcohol	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	D001569
fluvoxamine maleate	Benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	D001569
fluvoxamine maleate	Benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	D001569
fluvoxamine maleate	Benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	D001569
fluvoxamine maleate	Diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	Diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	fluvoxamine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	34	35	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	35	35	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		D016666	D016666
fluvoxamine maleate	fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	43	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		D016666	D016666
fluvoxamine maleate	fluvoxamine	41	43	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	41	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		D016666	D016666
fluvoxamine maleate	fluvoxamine	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		D016666	D016666
fluvoxamine maleate	fluvoxamine	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		D016666	D016666
fluvoxamine maleate	fluvoxamine	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		D016666	D016666
fluvoxamine maleate	fluvoxamine	12	12	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		D016666	D016666
fluvoxamine maleate	fluvoxamine	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	51	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	50	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	49	50	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	19	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	19	21	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	19	20	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	48	50	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	21	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	21	23	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	20	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	24	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	24	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	56	55	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		D016666	D016666
fluvoxamine maleate	fluvoxamine	56	56	false	none	7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		D016666	D016666
fluvoxamine maleate	Lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine maleate	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine maleate	pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine maleate	pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine maleate	warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	11289	D016666	D014859
fluvoxamine maleate	warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	11289	D016666	D014859
fluvoxamine maleate	warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	11289	D016666	D014859
fluvoxamine maleate	warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	11289	D016666	D014859
fluvoxamine maleate	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	5691	D016666	5691
fluvoxamine maleate	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	5691	D016666	5691
fluvoxamine maleate	imipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	5691	D016666	5691
fluvoxamine maleate	imipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	5691	D016666	5691
fluvoxamine maleate	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	Carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	Carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	0	D016666	D002997
fluvoxamine maleate	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	0	D016666	D002997
fluvoxamine maleate	clomipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	0	D016666	D002997
fluvoxamine maleate	clomipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	0	D016666	D002997
fluvoxamine maleate	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	596	D016666	D000525
fluvoxamine maleate	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	596	D016666	D000525
fluvoxamine maleate	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	atenolol	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	704	D016666	704
fluvoxamine maleate	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	704	D016666	704
fluvoxamine maleate	amitriptyline	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	704	D016666	704
fluvoxamine maleate	amitriptyline	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	704	D016666	704
fluvoxamine maleate	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine maleate	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine maleate	Tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	Tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	Tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	Tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	p450	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	p450	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	phenytoin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8183	D016666	D010672
fluvoxamine maleate	phenytoin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8183	D016666	D010672
fluvoxamine maleate	alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine maleate	alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	none	D016666	none
fluvoxamine maleate	alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	none	D016666	none
fluvoxamine maleate	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	4493	D016666	D005473
fluvoxamine maleate	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	4493	D016666	D005473
fluvoxamine maleate	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine maleate	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine maleate	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine maleate	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine maleate	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine maleate	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine maleate	serotonin	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine maleate	serotonin	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine maleate	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine maleate	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine maleate	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine maleate	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine maleate	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	448	D016666	D000431
fluvoxamine maleate	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	448	D016666	D000431
fluvoxamine maleate	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	448	D016666	D000431
fluvoxamine maleate	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	448	D016666	D000431
fluvoxamine maleate	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine maleate	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine maleate	tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine maleate	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	0	D016666	261563
fluvoxamine maleate	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	0	D016666	261563
fluvoxamine maleate	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	0	D016666	261563
fluvoxamine maleate	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	0	D016666	261563
fluvoxamine maleate	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	0	D016666	261563
fluvoxamine maleate	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	0	D016666	261563
fluvoxamine maleate	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine maleate	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine maleate	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine maleate	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine maleate	Clozapine	24	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	2626	D016666	D003024
fluvoxamine maleate	Clozapine	24	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	2626	D016666	D003024
fluvoxamine maleate	benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	D001569
fluvoxamine maleate	benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	D001569
fluvoxamine maleate	benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	D001569
fluvoxamine maleate	benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	D001569
fluvoxamine maleate	Theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine maleate	Theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine maleate	Theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine maleate	Pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine maleate	Pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine maleate	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	57258	D016666	C023754
fluvoxamine maleate	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	57258	D016666	C023754
fluvoxamine maleate	Tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	57258	D016666	C023754
fluvoxamine maleate	Tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	57258	D016666	C023754
fluvoxamine maleate	Propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	metoprolol	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine maleate	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	10502	D016666	D013881
fluvoxamine maleate	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	10502	D016666	D013881
fluvoxamine maleate	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine maleate	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine maleate	triptan	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine maleate	triptan	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine maleate	triptan	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	triptan	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine maleate	omeprazole	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	7646	D016666	D009853
fluvoxamine maleate	omeprazole	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	7646	D016666	D009853
Methadone	Fluvoxamine	25	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	none	D008691	none
Methadone	Fluvoxamine	25	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	none	D008691	none
Methadone	Fluvoxamine	25	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	none	D008691	none
Methadone	Fluvoxamine	25	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	none	D008691	none
Methadone	fluvoxamine	25	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	42355	D008691	D016666
Methadone	fluvoxamine	25	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	42355	D008691	D016666
Methadone	fluvoxamine	25	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	42355	D008691	D016666
Methadone	fluvoxamine	25	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).  		6813	42355	D008691	D016666
Methadone	pimozide	25	27	false	none	Methadone: See WARNINGS AND PRECAUTIONS (5.8).  Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.2).  Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  		6813	8331	D008691	D010868
Methadone	pimozide	25	27	false	none	Methadone: See WARNINGS AND PRECAUTIONS (5.8).  Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.2).  Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  		6813	8331	D008691	D010868
Methadone	Pimozide	25	27	false	none	Methadone: See WARNINGS AND PRECAUTIONS (5.8).  Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.2).  Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  		6813	8331	D008691	D010868
Methadone	Pimozide	25	27	false	none	Methadone: See WARNINGS AND PRECAUTIONS (5.8).  Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.2).  Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  		6813	8331	D008691	D010868
paroxetine	Fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	Fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	Fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	Fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	Fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	none	D017374	none
paroxetine	Fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	none	D017374	none
paroxetine	Fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	none	D017374	none
paroxetine	Fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	none	D017374	none
paroxetine	sumatriptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	37418	D017374	D018170
paroxetine	sumatriptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	37418	D017374	D018170
paroxetine	sumatriptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	37418	D017374	D018170
paroxetine	sumatriptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	37418	D017374	D018170
paroxetine	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	36437	D017374	D020280
paroxetine	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	36437	D017374	D020280
paroxetine	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	42355	D017374	D016666
paroxetine	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	42355	D017374	D016666
paroxetine	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	42355	D017374	D016666
paroxetine	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	42355	D017374	D016666
paroxetine	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	42355	D017374	D016666
paroxetine	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	42355	D017374	D016666
paroxetine	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	42355	D017374	D016666
paroxetine	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	42355	D017374	D016666
paroxetine	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	10898	D017374	D014364
paroxetine	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	10898	D017374	D014364
paroxetine	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	10898	D017374	D014364
paroxetine	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	10898	D017374	D014364
paroxetine	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	4493	D017374	D005473
paroxetine	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	4493	D017374	D005473
paroxetine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	1311214	D017374	D012701
paroxetine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	1311214	D017374	D012701
paroxetine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	10898	D017374	D014364
paroxetine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		32937	10898	D017374	D014364
paroxetine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	10898	D017374	D014364
paroxetine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		32937	10898	D017374	D014364
paroxetine	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
paroxetine	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		32937	none	D017374	none
Fluvoxamine	quinidine	7	9	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		none	9068	none	9068
Fluvoxamine	quinidine	7	9	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		none	9068	none	9068
Fluvoxamine	quinidine	8	9	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		none	9068	none	9068
Fluvoxamine	quinidine	8	9	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		none	9068	none	9068
Fluvoxamine	quinidine	10	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	9068	none	9068
Fluvoxamine	quinidine	10	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	9068	none	9068
Fluvoxamine	quinidine	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	9068	none	9068
Fluvoxamine	quinidine	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	9068	none	9068
Fluvoxamine	Warfarin	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	Warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	Warfarin	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	none	none	none
Fluvoxamine	Warfarin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Fluvoxamine	Warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Fluvoxamine	Warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	none	none	none
Fluvoxamine	Warfarin	55	54	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	none	none	none
Fluvoxamine	Warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	none	none	none
Fluvoxamine	tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	tizanidine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	57258	none	C023754
Fluvoxamine	tizanidine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	57258	none	C023754
Fluvoxamine	tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	57258	none	C023754
Fluvoxamine	tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	57258	none	C023754
Fluvoxamine	tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	57258	none	C023754
Fluvoxamine	tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	57258	none	C023754
Fluvoxamine	Alprazolam	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	Alprazolam	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	Alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	Alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	Alprazolam	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	596	none	D000525
Fluvoxamine	Alprazolam	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	596	none	D000525
Fluvoxamine	Alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	596	none	D000525
Fluvoxamine	Alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	596	none	D000525
Fluvoxamine	Digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
Fluvoxamine	Digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
Fluvoxamine	Digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Fluvoxamine	Ramelteon	30	28	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	596205	none	596205
Fluvoxamine	Ramelteon	30	28	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	596205	none	596205
Fluvoxamine	Alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	85248	none	C090840
Fluvoxamine	Alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	85248	none	C090840
Fluvoxamine	Alosetron	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	85248	none	C090840
Fluvoxamine	Alosetron	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	85248	none	C090840
Fluvoxamine	Alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	85248	none	C090840
Fluvoxamine	Alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	85248	none	C090840
Fluvoxamine	Alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	85248	none	C090840
Fluvoxamine	Alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	85248	none	C090840
Fluvoxamine	theophylline	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	10438	none	D013806
Fluvoxamine	theophylline	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	10438	none	D013806
Fluvoxamine	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	10438	none	D013806
Fluvoxamine	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	10438	none	D013806
Fluvoxamine	theophylline	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	10438	none	D013806
Fluvoxamine	theophylline	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	10438	none	D013806
Fluvoxamine	theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	10438	none	D013806
Fluvoxamine	theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	10438	none	D013806
Fluvoxamine	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	10438	none	D013806
Fluvoxamine	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	10438	none	D013806
Fluvoxamine	theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	10438	none	D013806
Fluvoxamine	theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	10438	none	D013806
Fluvoxamine	theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		none	10438	none	D013806
Fluvoxamine	theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		none	10438	none	D013806
Fluvoxamine	theophylline	55	53	true	positive	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	10438	none	D013806
Fluvoxamine	theophylline	55	53	true	positive	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	10438	none	D013806
Fluvoxamine	debrisoquin	4	6	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		none	3118	none	D003647
Fluvoxamine	debrisoquin	4	6	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		none	3118	none	D003647
Fluvoxamine	debrisoquin	7	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		none	3118	none	D003647
Fluvoxamine	debrisoquin	7	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		none	3118	none	D003647
Fluvoxamine	debrisoquin	8	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	3118	none	D003647
Fluvoxamine	debrisoquin	8	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	3118	none	D003647
Fluvoxamine	ketoconazole	8	10	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	6135	none	D007654
Fluvoxamine	ketoconazole	8	10	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	6135	none	D007654
Fluvoxamine	ketoconazole	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	6135	none	D007654
Fluvoxamine	ketoconazole	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	6135	none	D007654
Fluvoxamine	ketoconazole	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	6135	none	D007654
Fluvoxamine	ketoconazole	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	6135	none	D007654
Fluvoxamine	ketoconazole	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	6135	none	D007654
Fluvoxamine	ketoconazole	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	6135	none	D007654
Fluvoxamine	propranolol	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	8787	none	D011433
Fluvoxamine	propranolol	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	8787	none	D011433
Fluvoxamine	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	8787	none	D011433
Fluvoxamine	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	8787	none	D011433
Fluvoxamine	propranolol	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	8787	none	D011433
Fluvoxamine	propranolol	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	8787	none	D011433
Fluvoxamine	propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	8787	none	D011433
Fluvoxamine	propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	8787	none	D011433
Fluvoxamine	propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		none	8787	none	D011433
Fluvoxamine	propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		none	8787	none	D011433
Fluvoxamine	propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	8787	none	D011433
Fluvoxamine	propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	8787	none	D011433
Fluvoxamine	propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	8787	none	D011433
Fluvoxamine	propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	8787	none	D011433
Fluvoxamine	propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	8787	none	D011433
Fluvoxamine	propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	8787	none	D011433
Fluvoxamine	propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	8787	none	D011433
Fluvoxamine	propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	8787	none	D011433
Fluvoxamine	propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	8787	none	D011433
Fluvoxamine	propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	8787	none	D011433
Fluvoxamine	propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	8787	none	D011433
Fluvoxamine	propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	8787	none	D011433
Fluvoxamine	propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	8787	none	D011433
Fluvoxamine	propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	8787	none	D011433
Fluvoxamine	propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	8787	none	D011433
Fluvoxamine	propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	8787	none	D011433
Fluvoxamine	propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	8787	none	D011433
Fluvoxamine	propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	8787	none	D011433
Fluvoxamine	propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	8787	none	D011433
Fluvoxamine	propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	8787	none	D011433
Fluvoxamine	Mexiletine	43	45	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Fluvoxamine	Mexiletine	46	45	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
Fluvoxamine	Mexiletine	44	45	false	none	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Fluvoxamine	Aspirin	55	54	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	none	none	none
Fluvoxamine	Aspirin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	none	none	none
Fluvoxamine	sumatriptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	37418	none	D018170
Fluvoxamine	sumatriptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	37418	none	D018170
Fluvoxamine	sumatriptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	37418	none	D018170
Fluvoxamine	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	36437	none	D020280
Fluvoxamine	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	36437	none	D020280
Fluvoxamine	sertraline	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	36437	none	D020280
Fluvoxamine	sertraline	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	36437	none	D020280
Fluvoxamine	sertraline	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	36437	none	D020280
Fluvoxamine	sertraline	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	36437	none	D020280
Fluvoxamine	sertraline	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	36437	none	D020280
Fluvoxamine	sertraline	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	36437	none	D020280
Fluvoxamine	alcohol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	none	none	none
Fluvoxamine	alcohol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	none	none	none
Fluvoxamine	alcohol	19	20	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	none	none	none
Fluvoxamine	alcohol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	none	none	none
Fluvoxamine	alcohol	18	20	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	none	none	none
Fluvoxamine	alcohol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	none	none	none
Fluvoxamine	alcohol	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	none	none	none
Fluvoxamine	alcohol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	none	none	none
Fluvoxamine	alcohol	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	none	none	none
Fluvoxamine	Benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
Fluvoxamine	Benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
Fluvoxamine	Benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	none	none	D001569
Fluvoxamine	Benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	D001569
Fluvoxamine	Diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Fluvoxamine	Diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
Fluvoxamine	Diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Fluvoxamine	fluvoxamine	2	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	2	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	2	4	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	2	4	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	4	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	4	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	4	4	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	4	4	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	7	7	true	positive	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	7	7	true	positive	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	7	8	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	7	8	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	8	7	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	8	7	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	8	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	8	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	8	10	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	8	10	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	12	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	10	12	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	12	12	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	12	12	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	21	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	21	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	20	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	19	20	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	19	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	19	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	20	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	18	20	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	20	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	23	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	21	23	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	19	false	none	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	23	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	23	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	23	24	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	23	24	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	24	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	24	23	false	none	Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	24	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	24	24	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	34	35	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	34	35	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	35	35	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	35	35	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	37	35	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	37	35	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	37	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	37	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	43	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	43	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	40	41	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	40	41	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	43	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	43	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	51	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	51	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	50	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	50	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	50	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	50	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	55	55	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	55	55	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	55	56	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	55	56	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	56	55	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	56	55	true	positive	7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	56	56	false	none	7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Fluvoxamine	fluvoxamine	56	56	false	none	7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Fluvoxamine	Lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
Fluvoxamine	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
Fluvoxamine	pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	8331	none	D010868
Fluvoxamine	pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	8331	none	D010868
Fluvoxamine	warfarin	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	11289	none	D014859
Fluvoxamine	warfarin	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	11289	none	D014859
Fluvoxamine	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	11289	none	D014859
Fluvoxamine	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	11289	none	D014859
Fluvoxamine	warfarin	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	11289	none	D014859
Fluvoxamine	warfarin	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	11289	none	D014859
Fluvoxamine	warfarin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	none	D014859
Fluvoxamine	warfarin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	none	D014859
Fluvoxamine	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	none	D014859
Fluvoxamine	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	none	D014859
Fluvoxamine	warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	11289	none	D014859
Fluvoxamine	warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	11289	none	D014859
Fluvoxamine	warfarin	55	54	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	11289	none	D014859
Fluvoxamine	warfarin	55	54	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	11289	none	D014859
Fluvoxamine	warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	11289	none	D014859
Fluvoxamine	warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	11289	none	D014859
Fluvoxamine	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	5691	none	5691
Fluvoxamine	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	5691	none	5691
Fluvoxamine	imipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	5691	none	5691
Fluvoxamine	imipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	5691	none	5691
Fluvoxamine	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	Carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	Carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	Carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	2002	none	D002220
Fluvoxamine	Carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	2002	none	D002220
Fluvoxamine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	0	none	D002997
Fluvoxamine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	0	none	D002997
Fluvoxamine	clomipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	0	none	D002997
Fluvoxamine	clomipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	0	none	D002997
Fluvoxamine	alprazolam	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	alprazolam	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Fluvoxamine	alprazolam	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	596	none	D000525
Fluvoxamine	alprazolam	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	596	none	D000525
Fluvoxamine	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	596	none	D000525
Fluvoxamine	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	596	none	D000525
Fluvoxamine	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
Fluvoxamine	digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
Fluvoxamine	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Fluvoxamine	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	none	none	none
Fluvoxamine	atenolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Fluvoxamine	atenolol	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	none	none	none
Fluvoxamine	atenolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Fluvoxamine	atenolol	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	none	none	none
Fluvoxamine	Tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		none	10318	none	D013619
Fluvoxamine	Tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		none	10318	none	D013619
Fluvoxamine	Tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	10318	none	D013619
Fluvoxamine	Tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	10318	none	D013619
Fluvoxamine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	704	none	704
Fluvoxamine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	704	none	704
Fluvoxamine	amitriptyline	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	704	none	704
Fluvoxamine	amitriptyline	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	704	none	704
Fluvoxamine	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Fluvoxamine	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Fluvoxamine	Tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	Tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	Tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	p450	2	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		none	none	none	none
Fluvoxamine	p450	2	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		none	none	none	none
Fluvoxamine	p450	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	p450	4	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	none	none	none
Fluvoxamine	p450	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	none	none	none
Fluvoxamine	p450	7	9	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		none	none	none	none
Fluvoxamine	p450	8	9	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		none	none	none	none
Fluvoxamine	p450	8	10	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	none	none	none
Fluvoxamine	p450	10	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	none	none	none
Fluvoxamine	p450	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		none	none	none	none
Fluvoxamine	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Fluvoxamine	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Fluvoxamine	p450	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	none	none	none
Fluvoxamine	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
Fluvoxamine	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
Fluvoxamine	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
Fluvoxamine	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
Fluvoxamine	phenytoin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	8183	none	D010672
Fluvoxamine	phenytoin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	8183	none	D010672
Fluvoxamine	alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
Fluvoxamine	alosetron	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	none	none	none
Fluvoxamine	alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	none	none	none
Fluvoxamine	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Fluvoxamine	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	4493	none	D005473
Fluvoxamine	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	4493	none	D005473
Fluvoxamine	fluoxetine	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	4493	none	D005473
Fluvoxamine	fluoxetine	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	4493	none	D005473
Fluvoxamine	fluoxetine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	4493	none	D005473
Fluvoxamine	fluoxetine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	4493	none	D005473
Fluvoxamine	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	4493	none	D005473
Fluvoxamine	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	4493	none	D005473
Fluvoxamine	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Fluvoxamine	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
Fluvoxamine	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Fluvoxamine	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	6470	none	D008140
Fluvoxamine	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		none	6470	none	D008140
Fluvoxamine	lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
Fluvoxamine	lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		none	6470	none	D008140
Fluvoxamine	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
Fluvoxamine	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
Fluvoxamine	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
Fluvoxamine	carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	2002	none	D002220
Fluvoxamine	carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	2002	none	D002220
Fluvoxamine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	1311214	none	D012701
Fluvoxamine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	1311214	none	D012701
Fluvoxamine	serotonin	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	1311214	none	D012701
Fluvoxamine	serotonin	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	1311214	none	D012701
Fluvoxamine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	1311214	none	D012701
Fluvoxamine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	1311214	none	D012701
Fluvoxamine	serotonin	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		none	1311214	none	D012701
Fluvoxamine	serotonin	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		none	1311214	none	D012701
Fluvoxamine	serotonin	37	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	1311214	none	D012701
Fluvoxamine	serotonin	37	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	1311214	none	D012701
Fluvoxamine	serotonin	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	1311214	none	D012701
Fluvoxamine	serotonin	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	1311214	none	D012701
Fluvoxamine	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
Fluvoxamine	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
Fluvoxamine	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
Fluvoxamine	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
Fluvoxamine	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
Fluvoxamine	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
Fluvoxamine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	448	none	D000431
Fluvoxamine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	448	none	D000431
Fluvoxamine	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	448	none	D000431
Fluvoxamine	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	448	none	D000431
Fluvoxamine	tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		none	10318	none	D013619
Fluvoxamine	tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		none	10318	none	D013619
Fluvoxamine	tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	10318	none	D013619
Fluvoxamine	tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		none	10318	none	D013619
Fluvoxamine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Fluvoxamine	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Fluvoxamine	tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	10898	none	D014364
Fluvoxamine	tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	10898	none	D014364
Fluvoxamine	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	0	none	261563
Fluvoxamine	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	0	none	261563
Fluvoxamine	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	0	none	261563
Fluvoxamine	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	0	none	261563
Fluvoxamine	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	0	none	261563
Fluvoxamine	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	0	none	261563
Fluvoxamine	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	0	none	261563
Fluvoxamine	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	0	none	261563
Fluvoxamine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		none	2626	none	D003024
Fluvoxamine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		none	2626	none	D003024
Fluvoxamine	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		none	2626	none	D003024
Fluvoxamine	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		none	2626	none	D003024
Fluvoxamine	Clozapine	23	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	2626	none	D003024
Fluvoxamine	Clozapine	23	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		none	2626	none	D003024
Fluvoxamine	Clozapine	24	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	2626	none	D003024
Fluvoxamine	Clozapine	24	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		none	2626	none	D003024
Fluvoxamine	benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
Fluvoxamine	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
Fluvoxamine	benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	none	none	D001569
Fluvoxamine	benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	D001569
Fluvoxamine	Theophylline	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	Theophylline	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	none	none	none
Fluvoxamine	Theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Fluvoxamine	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Fluvoxamine	Theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	none	none	none
Fluvoxamine	Theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Fluvoxamine	Theophylline	55	53	true	positive	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	none	none	none
Fluvoxamine	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Fluvoxamine	Pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	8331	none	D010868
Fluvoxamine	Pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	8331	none	D010868
Fluvoxamine	dextromethorphan	4	6	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		none	0	none	D003915
Fluvoxamine	dextromethorphan	4	6	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		none	0	none	D003915
Fluvoxamine	dextromethorphan	7	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		none	0	none	D003915
Fluvoxamine	dextromethorphan	7	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		none	0	none	D003915
Fluvoxamine	dextromethorphan	8	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	0	none	D003915
Fluvoxamine	dextromethorphan	8	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		none	0	none	D003915
Fluvoxamine	Tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	Tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Fluvoxamine	Tizanidine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	57258	none	C023754
Fluvoxamine	Tizanidine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	57258	none	C023754
Fluvoxamine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	57258	none	C023754
Fluvoxamine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	57258	none	C023754
Fluvoxamine	Tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	57258	none	C023754
Fluvoxamine	Tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		none	57258	none	C023754
Fluvoxamine	Propranolol	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Fluvoxamine	Propranolol	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	none	none	none
Fluvoxamine	Propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
Fluvoxamine	Propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		none	none	none	none
Fluvoxamine	Propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
Fluvoxamine	Propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	none	none	none
Fluvoxamine	Propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Fluvoxamine	Propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	none	none	none
Fluvoxamine	Propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Fluvoxamine	Propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Fluvoxamine	Propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Fluvoxamine	Propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Fluvoxamine	Propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	none	none	none
Fluvoxamine	Propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	none	none	none
Fluvoxamine	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	none	none	none
Fluvoxamine	metoprolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	none	none	none
Fluvoxamine	metoprolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Fluvoxamine	metoprolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	none	none	none
Fluvoxamine	metoprolol	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		none	none	none	none
Fluvoxamine	metoprolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Fluvoxamine	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Fluvoxamine	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Fluvoxamine	metoprolol	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Fluvoxamine	metoprolol	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	none	none	none
Fluvoxamine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		none	10502	none	D013881
Fluvoxamine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		none	10502	none	D013881
Fluvoxamine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	10502	none	D013881
Fluvoxamine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		none	10502	none	D013881
Fluvoxamine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Fluvoxamine	triptan	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		none	none	none	none
Fluvoxamine	triptan	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	none	none	none
Fluvoxamine	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	none	none	none
Fluvoxamine	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	none	none	none
Fluvoxamine	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	none	none	none
Fluvoxamine	triptan	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		none	none	none	none
Fluvoxamine	triptan	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		none	none	none	none
Fluvoxamine	triptan	37	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	none	none	none
Fluvoxamine	triptan	37	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		none	none	none	none
Fluvoxamine	triptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	none	none	none
Fluvoxamine	triptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		none	none	none	none
Fluvoxamine	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		none	none	none	none
Fluvoxamine	omeprazole	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Fluvoxamine	omeprazole	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Fluvoxamine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Fluvoxamine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Fluvoxamine	omeprazole	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	7646	none	D009853
Fluvoxamine	omeprazole	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	7646	none	D009853
Fluvoxamine	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
Fluvoxamine	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
Fluvoxamine	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
Fluvoxamine	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
Fluvoxamine	omeprazole	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	7646	none	D009853
Fluvoxamine	omeprazole	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	7646	none	D009853
quinidine	Warfarin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	none
quinidine	Warfarin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	none
quinidine	theophylline	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	10438	9068	D013806
quinidine	theophylline	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	10438	9068	D013806
quinidine	ketoconazole	9	10	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		9068	6135	9068	D007654
quinidine	ketoconazole	9	10	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		9068	6135	9068	D007654
quinidine	Benzodiazepines	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	D001569
quinidine	Benzodiazepines	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	D001569
quinidine	fluvoxamine	9	7	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		9068	42355	9068	D016666
quinidine	fluvoxamine	9	7	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		9068	42355	9068	D016666
quinidine	fluvoxamine	9	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		9068	42355	9068	D016666
quinidine	fluvoxamine	9	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		9068	42355	9068	D016666
quinidine	fluvoxamine	9	10	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		9068	42355	9068	D016666
quinidine	fluvoxamine	9	10	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		9068	42355	9068	D016666
quinidine	fluvoxamine	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	42355	9068	D016666
quinidine	fluvoxamine	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	42355	9068	D016666
quinidine	pimozide	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	8331	9068	D010868
quinidine	pimozide	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	8331	9068	D010868
quinidine	warfarin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	11289	9068	D014859
quinidine	warfarin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	11289	9068	D014859
quinidine	p450	9	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		9068	none	9068	none
quinidine	p450	9	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		9068	none	9068	none
quinidine	p450	9	10	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		9068	none	9068	none
quinidine	p450	9	10	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		9068	none	9068	none
quinidine	phenytoin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	8183	9068	D010672
quinidine	phenytoin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	8183	9068	D010672
quinidine	benzodiazepines	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	D001569
quinidine	benzodiazepines	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	D001569
quinidine	Theophylline	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	none
quinidine	Theophylline	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	none	9068	none
quinidine	Pimozide	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	8331	9068	D010868
quinidine	Pimozide	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	8331	9068	D010868
quinidine	omeprazole	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	7646	9068	D009853
quinidine	omeprazole	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		9068	7646	9068	D009853
Warfarin	tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Warfarin	tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Warfarin	Alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Warfarin	Alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Warfarin	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	10438	none	D013806
Warfarin	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	10438	none	D013806
Warfarin	theophylline	54	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	10438	none	D013806
Warfarin	theophylline	54	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	10438	none	D013806
Warfarin	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	10438	none	D013806
Warfarin	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	10438	none	D013806
Warfarin	ketoconazole	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	6135	none	D007654
Warfarin	ketoconazole	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	6135	none	D007654
Warfarin	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	8787	none	D011433
Warfarin	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	8787	none	D011433
Warfarin	propranolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	8787	none	D011433
Warfarin	propranolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	8787	none	D011433
Warfarin	Aspirin	54	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Warfarin	Benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
Warfarin	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Warfarin	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Warfarin	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Warfarin	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	42355	none	D016666
Warfarin	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Warfarin	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		none	42355	none	D016666
Warfarin	fluvoxamine	54	55	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	42355	none	D016666
Warfarin	fluvoxamine	54	55	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	42355	none	D016666
Warfarin	fluvoxamine	54	56	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Warfarin	fluvoxamine	54	56	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Warfarin	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Warfarin	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Warfarin	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Warfarin	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	none	D016666
Warfarin	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Warfarin	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	none	D016666
Warfarin	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Warfarin	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Warfarin	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	11289	none	D014859
Warfarin	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	11289	none	D014859
Warfarin	warfarin	54	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	11289	none	D014859
Warfarin	warfarin	54	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	11289	none	D014859
Warfarin	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	none	D014859
Warfarin	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	none	D014859
Warfarin	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Warfarin	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	596	none	D000525
Warfarin	atenolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Warfarin	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Warfarin	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Warfarin	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Warfarin	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Warfarin	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Warfarin	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
Warfarin	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
Warfarin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
Warfarin	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Warfarin	Theophylline	54	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Warfarin	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
Warfarin	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Warfarin	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Warfarin	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Warfarin	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Warfarin	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Warfarin	Propranolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Warfarin	metoprolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Warfarin	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Warfarin	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Warfarin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
Warfarin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
tizanidine	Alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	596	C023754	D000525
tizanidine	Alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	596	C023754	D000525
tizanidine	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	10438	C023754	D013806
tizanidine	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	10438	C023754	D013806
tizanidine	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	8787	C023754	D011433
tizanidine	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	8787	C023754	D011433
tizanidine	fluvoxamine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	33	35	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	33	35	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		57258	42355	C023754	D016666
tizanidine	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		57258	42355	C023754	D016666
tizanidine	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	11289	C023754	D014859
tizanidine	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	11289	C023754	D014859
tizanidine	imipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	5691	C023754	5691
tizanidine	imipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	5691	C023754	5691
tizanidine	clomipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	0	C023754	D002997
tizanidine	clomipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	0	C023754	D002997
tizanidine	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	596	C023754	D000525
tizanidine	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	596	C023754	D000525
tizanidine	Tacrine	33	31	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10318	C023754	D013619
tizanidine	Tacrine	33	31	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10318	C023754	D013619
tizanidine	amitriptyline	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	704	C023754	704
tizanidine	amitriptyline	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		57258	704	C023754	704
tizanidine	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	tacrine	33	31	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10318	C023754	D013619
tizanidine	tacrine	33	31	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10318	C023754	D013619
tizanidine	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	Tizanidine	33	33	false	none	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		C023754	C023754
tizanidine	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		C023754	C023754
tizanidine	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
tizanidine	Thioridazine	33	32	false	none	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10502	C023754	D013881
tizanidine	Thioridazine	33	32	false	none	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10502	C023754	D013881
tizanidine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	7646	C023754	D009853
tizanidine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	7646	C023754	D009853
Alprazolam	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	10438	D000525	D013806
Alprazolam	theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	10438	D000525	D013806
Alprazolam	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	8787	D000525	D011433
Alprazolam	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	8787	D000525	D011433
Alprazolam	Benzodiazepines	15	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		596	none	D000525	D001569
Alprazolam	Benzodiazepines	15	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		596	none	D000525	D001569
Alprazolam	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	42355	D000525	D016666
Alprazolam	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	42355	D000525	D016666
Alprazolam	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	42355	D000525	D016666
Alprazolam	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	42355	D000525	D016666
Alprazolam	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		596	42355	D000525	D016666
Alprazolam	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		596	42355	D000525	D016666
Alprazolam	fluvoxamine	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	42355	D000525	D016666
Alprazolam	fluvoxamine	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	42355	D000525	D016666
Alprazolam	Lorazepam	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	6470	D000525	D008140
Alprazolam	Lorazepam	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	6470	D000525	D008140
Alprazolam	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	11289	D000525	D014859
Alprazolam	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	11289	D000525	D014859
Alprazolam	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		D000525	D000525
Alprazolam	alprazolam	15	15	false	none	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		D000525	D000525
Alprazolam	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	lorazepam	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	6470	D000525	D008140
Alprazolam	lorazepam	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	6470	D000525	D008140
Alprazolam	benzodiazepines	15	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		596	none	D000525	D001569
Alprazolam	benzodiazepines	15	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		596	none	D000525	D001569
Alprazolam	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	57258	D000525	C023754
Alprazolam	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	57258	D000525	C023754
Alprazolam	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
Alprazolam	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	7646	D000525	D009853
Alprazolam	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	7646	D000525	D009853
Digoxin	Alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	85248	none	C090840
Digoxin	Alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	85248	none	C090840
Digoxin	Mexiletine	43	45	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Digoxin	Diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Digoxin	fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Digoxin	fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Digoxin	fluvoxamine	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Digoxin	fluvoxamine	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	42355	none	D016666
Digoxin	fluvoxamine	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Digoxin	fluvoxamine	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Digoxin	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
Digoxin	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Digoxin	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Digoxin	alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
Digoxin	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Digoxin	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Digoxin	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
Digoxin	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	0	none	261563
Digoxin	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	0	none	261563
Ramelteon	fluvoxamine	28	30	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		596205	42355	596205	D016666
Ramelteon	fluvoxamine	28	30	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		596205	42355	596205	D016666
Ramelteon	pimozide	28	27	false	none	Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  		596205	8331	596205	D010868
Ramelteon	pimozide	28	27	false	none	Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  		596205	8331	596205	D010868
Ramelteon	Tacrine	28	30	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		596205	10318	596205	D013619
Ramelteon	Tacrine	28	30	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		596205	10318	596205	D013619
Ramelteon	tacrine	28	30	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		596205	10318	596205	D013619
Ramelteon	tacrine	28	30	false	none	Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  Serotonergic Drugs: See WARNINGS AND PRECAUTIONS (5.3).  Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		596205	10318	596205	D013619
Ramelteon	Pimozide	28	27	false	none	Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  		596205	8331	596205	D010868
Ramelteon	Pimozide	28	27	false	none	Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  Ramelteon: See WARNINGS AND PRECAUTIONS (5.8).  		596205	8331	596205	D010868
Alosetron	Diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		85248	none	C090840	none
Alosetron	Diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		85248	none	C090840	none
Alosetron	fluvoxamine	42	43	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		85248	42355	C090840	D016666
Alosetron	fluvoxamine	42	43	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		85248	42355	C090840	D016666
Alosetron	fluvoxamine	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	42355	C090840	D016666
Alosetron	fluvoxamine	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	42355	C090840	D016666
Alosetron	fluvoxamine	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	42355	C090840	D016666
Alosetron	fluvoxamine	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	42355	C090840	D016666
Alosetron	fluvoxamine	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		85248	42355	C090840	D016666
Alosetron	fluvoxamine	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		85248	42355	C090840	D016666
Alosetron	digoxin	42	43	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		85248	none	C090840	none
Alosetron	digoxin	42	43	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		85248	none	C090840	none
Alosetron	Tryptophan	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	Tryptophan	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	Tryptophan	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	Tryptophan	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	alosetron	42	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	none	C090840	none
Alosetron	alosetron	42	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	none	C090840	none
Alosetron	diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		85248	none	C090840	none
Alosetron	diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		85248	none	C090840	none
Alosetron	tryptophan	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	tryptophan	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	tryptophan	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	tryptophan	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	10898	C090840	D014364
Alosetron	Lotronex	42	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	0	C090840	261563
Alosetron	Lotronex	42	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		85248	0	C090840	261563
theophylline	ketoconazole	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	6135	D013806	D007654
theophylline	ketoconazole	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	6135	D013806	D007654
theophylline	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	8787	D013806	D011433
theophylline	propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	8787	D013806	D011433
theophylline	propranolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	8787	D013806	D011433
theophylline	propranolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	8787	D013806	D011433
theophylline	Aspirin	53	54	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		10438	none	D013806	none
theophylline	Aspirin	53	54	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		10438	none	D013806	none
theophylline	Benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	D001569
theophylline	Benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	D001569
theophylline	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	42355	D013806	D016666
theophylline	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	42355	D013806	D016666
theophylline	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	42355	D013806	D016666
theophylline	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	42355	D013806	D016666
theophylline	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	53	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	42355	D013806	D016666
theophylline	fluvoxamine	53	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	42355	D013806	D016666
theophylline	fluvoxamine	53	55	true	positive	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	53	55	true	positive	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	42355	D013806	D016666
theophylline	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		10438	42355	D013806	D016666
theophylline	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		10438	42355	D013806	D016666
theophylline	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	8331	D013806	D010868
theophylline	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	8331	D013806	D010868
theophylline	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	11289	D013806	D014859
theophylline	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	11289	D013806	D014859
theophylline	warfarin	53	54	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		10438	11289	D013806	D014859
theophylline	warfarin	53	54	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		10438	11289	D013806	D014859
theophylline	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	11289	D013806	D014859
theophylline	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	11289	D013806	D014859
theophylline	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	596	D013806	D000525
theophylline	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	596	D013806	D000525
theophylline	atenolol	53	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	atenolol	53	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	atenolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	atenolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	none
theophylline	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	none
theophylline	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	none
theophylline	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	none
theophylline	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	8183	D013806	D010672
theophylline	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	8183	D013806	D010672
theophylline	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	D001569
theophylline	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	D001569
theophylline	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	Theophylline	53	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	Theophylline	53	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	none
theophylline	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	none	D013806	none
theophylline	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	8331	D013806	D010868
theophylline	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	8331	D013806	D010868
theophylline	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	57258	D013806	C023754
theophylline	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	57258	D013806	C023754
theophylline	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	none	D013806	none
theophylline	Propranolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	Propranolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	metoprolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	metoprolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		10438	none	D013806	none
theophylline	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	7646	D013806	D009853
theophylline	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		10438	7646	D013806	D009853
theophylline	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	7646	D013806	D009853
theophylline	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		10438	7646	D013806	D009853
debrisoquin	fluvoxamine	6	4	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		3118	42355	D003647	D016666
debrisoquin	fluvoxamine	6	4	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		3118	42355	D003647	D016666
debrisoquin	fluvoxamine	6	7	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		3118	42355	D003647	D016666
debrisoquin	fluvoxamine	6	7	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		3118	42355	D003647	D016666
debrisoquin	fluvoxamine	6	8	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		3118	42355	D003647	D016666
debrisoquin	fluvoxamine	6	8	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		3118	42355	D003647	D016666
debrisoquin	dextromethorphan	6	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		3118	0	D003647	D003915
debrisoquin	dextromethorphan	6	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		3118	0	D003647	D003915
ketoconazole	Benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	none	D007654	D001569
ketoconazole	Benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	none	D007654	D001569
ketoconazole	fluvoxamine	10	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	42355	D007654	D016666
ketoconazole	fluvoxamine	10	8	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	42355	D007654	D016666
ketoconazole	fluvoxamine	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	42355	D007654	D016666
ketoconazole	fluvoxamine	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	42355	D007654	D016666
ketoconazole	fluvoxamine	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	42355	D007654	D016666
ketoconazole	fluvoxamine	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	42355	D007654	D016666
ketoconazole	fluvoxamine	10	12	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		6135	42355	D007654	D016666
ketoconazole	fluvoxamine	10	12	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		6135	42355	D007654	D016666
ketoconazole	pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	8331	D007654	D010868
ketoconazole	pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	8331	D007654	D010868
ketoconazole	warfarin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	11289	D007654	D014859
ketoconazole	warfarin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	11289	D007654	D014859
ketoconazole	p450	10	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	none	D007654	none
ketoconazole	p450	10	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	none	D007654	none
ketoconazole	p450	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	none	D007654	none
ketoconazole	p450	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		6135	none	D007654	none
ketoconazole	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	8183	D007654	D010672
ketoconazole	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	8183	D007654	D010672
ketoconazole	benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	none	D007654	D001569
ketoconazole	benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	none	D007654	D001569
ketoconazole	Theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	none	D007654	none
ketoconazole	Theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	none	D007654	none
ketoconazole	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	8331	D007654	D010868
ketoconazole	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	8331	D007654	D010868
ketoconazole	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	7646	D007654	D009853
ketoconazole	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		6135	7646	D007654	D009853
propranolol	Mexiletine	46	45	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	Mexiletine	46	45	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	Mexiletine	47	45	false	none	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	Mexiletine	47	45	false	none	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	Aspirin	52	54	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		8787	none	D011433	none
propranolol	Aspirin	52	54	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		8787	none	D011433	none
propranolol	Diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	Diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	fluvoxamine	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	49	50	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	49	50	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	49	48	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	49	48	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	42355	D011433	D016666
propranolol	fluvoxamine	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	42355	D011433	D016666
propranolol	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	42355	D011433	D016666
propranolol	fluvoxamine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	42355	D011433	D016666
propranolol	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	3	4	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	52	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	52	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	52	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	52	50	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	47	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	47	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	47	49	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	47	49	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	47	48	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	42355	D011433	D016666
propranolol	fluvoxamine	47	48	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	42355	D011433	D016666
propranolol	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	11289	D011433	D014859
propranolol	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	11289	D011433	D014859
propranolol	warfarin	52	54	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		8787	11289	D011433	D014859
propranolol	warfarin	52	54	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		8787	11289	D011433	D014859
propranolol	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	596	D011433	D000525
propranolol	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	596	D011433	D000525
propranolol	atenolol	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		8787	none	D011433	none
propranolol	atenolol	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		8787	none	D011433	none
propranolol	atenolol	52	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	atenolol	52	51	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	atenolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	atenolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	Theophylline	52	53	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		8787	none	D011433	none
propranolol	Theophylline	52	53	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		8787	none	D011433	none
propranolol	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	57258	D011433	C023754
propranolol	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	57258	D011433	C023754
propranolol	Propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	Propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	Propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	Propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	none	D011433	none
propranolol	Propranolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	Propranolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	Propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	Propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		8787	none	D011433	none
propranolol	Propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	Propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	Propranolol	47	49	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	Propranolol	47	49	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	Propranolol	47	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	Propranolol	47	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	Propranolol	47	47	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	Propranolol	47	47	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		8787	none	D011433	none
propranolol	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	metoprolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	metoprolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		8787	none	D011433	none
propranolol	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	none	D011433	none
propranolol	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	none	D011433	none
propranolol	metoprolol	47	49	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	metoprolol	47	49	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		8787	none	D011433	none
propranolol	metoprolol	47	48	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	none	D011433	none
propranolol	metoprolol	47	48	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		8787	none	D011433	none
propranolol	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	7646	D011433	D009853
propranolol	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		8787	7646	D011433	D009853
Mexiletine	Diltiazem	45	44	false	none	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Mexiletine	fluvoxamine	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	42355	none	D016666
Mexiletine	fluvoxamine	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	42355	none	D016666
Mexiletine	fluvoxamine	45	46	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Mexiletine	fluvoxamine	45	46	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Mexiletine	fluvoxamine	45	44	false	none	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	42355	none	D016666
Mexiletine	fluvoxamine	45	44	false	none	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	42355	none	D016666
Mexiletine	digoxin	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Mexiletine	diltiazem	45	44	false	none	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Mexiletine	Propranolol	45	46	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
Mexiletine	Propranolol	45	47	false	none	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		none	none	none	none
Aspirin	fluvoxamine	54	55	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	42355	none	D016666
Aspirin	fluvoxamine	54	55	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		none	42355	none	D016666
Aspirin	fluvoxamine	54	56	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Aspirin	fluvoxamine	54	56	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		none	42355	none	D016666
Aspirin	warfarin	54	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	11289	none	D014859
Aspirin	warfarin	54	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	11289	none	D014859
Aspirin	atenolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Aspirin	Theophylline	54	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Aspirin	Propranolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
Aspirin	metoprolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		none	none	none	none
sumatriptan	sertraline	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
sumatriptan	sertraline	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
sumatriptan	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
sumatriptan	sertraline	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	36437	D018170	D020280
sumatriptan	fluvoxamine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	42355	D018170	D016666
sumatriptan	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	42355	D018170	D016666
sumatriptan	Tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	Tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
sumatriptan	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
sumatriptan	fluoxetine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
sumatriptan	fluoxetine	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
sumatriptan	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
sumatriptan	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	4493	D018170	D005473
sumatriptan	serotonin	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
sumatriptan	serotonin	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
sumatriptan	serotonin	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
sumatriptan	serotonin	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	1311214	D018170	D012701
sumatriptan	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	1311214	D018170	D012701
sumatriptan	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	1311214	D018170	D012701
sumatriptan	tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		37418	10898	D018170	D014364
sumatriptan	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
sumatriptan	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		37418	10898	D018170	D014364
sumatriptan	triptan	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
sumatriptan	triptan	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
sumatriptan	triptan	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sumatriptan	triptan	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sumatriptan	triptan	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
sumatriptan	triptan	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
sumatriptan	triptan	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
sumatriptan	triptan	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		37418	none	D018170	none
sumatriptan	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sumatriptan	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sumatriptan	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sumatriptan	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sumatriptan	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sumatriptan	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		37418	none	D018170	none
sertraline	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	42355	D020280	D016666
sertraline	fluvoxamine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	42355	D020280	D016666
sertraline	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	42355	D020280	D016666
sertraline	fluvoxamine	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	42355	D020280	D016666
sertraline	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		36437	42355	D020280	D016666
sertraline	fluvoxamine	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		36437	42355	D020280	D016666
sertraline	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		36437	42355	D020280	D016666
sertraline	fluvoxamine	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		36437	42355	D020280	D016666
sertraline	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		36437	10898	D020280	D014364
sertraline	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		36437	10898	D020280	D014364
sertraline	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		36437	10898	D020280	D014364
sertraline	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		36437	10898	D020280	D014364
sertraline	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	4493	D020280	D005473
sertraline	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	4493	D020280	D005473
sertraline	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	1311214	D020280	D012701
sertraline	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	1311214	D020280	D012701
sertraline	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		36437	10898	D020280	D014364
sertraline	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		36437	10898	D020280	D014364
sertraline	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		36437	10898	D020280	D014364
sertraline	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		36437	10898	D020280	D014364
sertraline	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	none	D020280	none
sertraline	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	none	D020280	none
sertraline	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	none	D020280	none
sertraline	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	none	D020280	none
sertraline	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	none	D020280	none
sertraline	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		36437	none	D020280	none
alcohol	fluvoxamine	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
alcohol	fluvoxamine	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
alcohol	fluvoxamine	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
alcohol	fluvoxamine	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
alcohol	fluvoxamine	19	18	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
alcohol	fluvoxamine	19	18	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	42355	none	D016666
alcohol	fluvoxamine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
alcohol	fluvoxamine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
alcohol	fluvoxamine	19	20	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	fluvoxamine	19	20	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	fluvoxamine	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	fluvoxamine	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	fluvoxamine	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	fluvoxamine	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	fluvoxamine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
alcohol	fluvoxamine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	42355	none	D016666
alcohol	fluvoxamine	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	fluvoxamine	20	20	false	none	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	42355	none	D016666
alcohol	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	Lorazepam	19	18	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	Lorazepam	19	18	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
alcohol	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
alcohol	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	lorazepam	19	18	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	lorazepam	19	18	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	6470	none	D008140
alcohol	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
alcohol	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	6470	none	D008140
alcohol	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		none	2002	none	D002220
alcohol	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
alcohol	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		none	448	none	D000431
alcohol	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	448	none	D000431
alcohol	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		none	448	none	D000431
alcohol	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		none	2626	none	D003024
alcohol	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		none	2626	none	D003024
Benzodiazepines	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	D001569	D016666
Benzodiazepines	fluvoxamine	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	D001569	D016666
Benzodiazepines	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	D001569	D016666
Benzodiazepines	fluvoxamine	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	42355	D001569	D016666
Benzodiazepines	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	D001569	D016666
Benzodiazepines	fluvoxamine	11	12	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		none	42355	D001569	D016666
Benzodiazepines	fluvoxamine	14	12	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		none	42355	D001569	D016666
Benzodiazepines	fluvoxamine	14	12	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		none	42355	D001569	D016666
Benzodiazepines	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	D001569	D010868
Benzodiazepines	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	D001569	D010868
Benzodiazepines	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	D001569	D014859
Benzodiazepines	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	11289	D001569	D014859
Benzodiazepines	alprazolam	14	15	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		none	596	D001569	D000525
Benzodiazepines	alprazolam	14	15	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		none	596	D001569	D000525
Benzodiazepines	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	D001569	none
Benzodiazepines	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	D001569	none
Benzodiazepines	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	D001569	D010672
Benzodiazepines	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	D001569	D010672
Benzodiazepines	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	D001569	D001569
Benzodiazepines	benzodiazepines	14	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	D001569	D001569
Benzodiazepines	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	D001569	none
Benzodiazepines	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	D001569	D010868
Benzodiazepines	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	D001569	D010868
Benzodiazepines	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	D001569	D009853
Benzodiazepines	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	D001569	D009853
Diltiazem	fluvoxamine	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Diltiazem	fluvoxamine	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Diltiazem	fluvoxamine	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Diltiazem	fluvoxamine	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	42355	none	D016666
Diltiazem	fluvoxamine	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Diltiazem	fluvoxamine	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	42355	none	D016666
Diltiazem	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Diltiazem	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Diltiazem	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
Diltiazem	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	0	none	261563
Diltiazem	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	0	none	261563
Diltiazem	Propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
fluvoxamine	Lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine	Lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine	pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine	pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine	warfarin	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	11289	D016666	D014859
fluvoxamine	warfarin	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	11289	D016666	D014859
fluvoxamine	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	11289	D016666	D014859
fluvoxamine	warfarin	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	11289	D016666	D014859
fluvoxamine	warfarin	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	11289	D016666	D014859
fluvoxamine	warfarin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	11289	D016666	D014859
fluvoxamine	warfarin	55	54	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	55	54	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	11289	D016666	D014859
fluvoxamine	warfarin	56	54	false	none	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  7.5 Electroconvulsive Therapy (ECT)    There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.  		42355	11289	D016666	D014859
fluvoxamine	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	5691	D016666	5691
fluvoxamine	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	5691	D016666	5691
fluvoxamine	imipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	5691	D016666	5691
fluvoxamine	imipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	5691	D016666	5691
fluvoxamine	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	Carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	Carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	Carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	Carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	Carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	2002	D016666	D002220
fluvoxamine	Carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	2002	D016666	D002220
fluvoxamine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	0	D016666	D002997
fluvoxamine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	0	D016666	D002997
fluvoxamine	clomipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	0	D016666	D002997
fluvoxamine	clomipramine	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	0	D016666	D002997
fluvoxamine	alprazolam	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	596	D016666	D000525
fluvoxamine	alprazolam	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	596	D016666	D000525
fluvoxamine	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	596	D016666	D000525
fluvoxamine	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	596	D016666	D000525
fluvoxamine	alprazolam	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	596	D016666	D000525
fluvoxamine	alprazolam	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	596	D016666	D000525
fluvoxamine	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	596	D016666	D000525
fluvoxamine	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	596	D016666	D000525
fluvoxamine	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine	digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine	digoxin	41	43	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	atenolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	atenolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	atenolol	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	atenolol	50	51	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	atenolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	atenolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	atenolol	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	atenolol	49	51	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	Tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		42355	10318	D016666	D013619
fluvoxamine	Tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		42355	10318	D016666	D013619
fluvoxamine	Tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		42355	10318	D016666	D013619
fluvoxamine	Tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		42355	10318	D016666	D013619
fluvoxamine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	704	D016666	704
fluvoxamine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	704	D016666	704
fluvoxamine	amitriptyline	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	704	D016666	704
fluvoxamine	amitriptyline	35	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	704	D016666	704
fluvoxamine	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	p450	2	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		42355	none	D016666	none
fluvoxamine	p450	2	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		42355	none	D016666	none
fluvoxamine	p450	2	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		42355	none	D016666	none
fluvoxamine	p450	2	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  		42355	none	D016666	none
fluvoxamine	p450	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	p450	4	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	p450	4	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	p450	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	p450	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	p450	7	9	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		42355	none	D016666	none
fluvoxamine	p450	7	9	false	none	While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		42355	none	D016666	none
fluvoxamine	p450	8	9	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		42355	none	D016666	none
fluvoxamine	p450	8	9	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  		42355	none	D016666	none
fluvoxamine	p450	8	10	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		42355	none	D016666	none
fluvoxamine	p450	8	10	false	none	This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		42355	none	D016666	none
fluvoxamine	p450	10	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		42355	none	D016666	none
fluvoxamine	p450	10	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		42355	none	D016666	none
fluvoxamine	p450	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		42355	none	D016666	none
fluvoxamine	p450	10	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  		42355	none	D016666	none
fluvoxamine	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	p450	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine	p450	12	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8183	D016666	D010672
fluvoxamine	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8183	D016666	D010672
fluvoxamine	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8183	D016666	D010672
fluvoxamine	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8183	D016666	D010672
fluvoxamine	phenytoin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8183	D016666	D010672
fluvoxamine	phenytoin	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8183	D016666	D010672
fluvoxamine	alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine	alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	none	D016666	none
fluvoxamine	alosetron	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	none	D016666	none
fluvoxamine	alosetron	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	none	D016666	none
fluvoxamine	alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	none	D016666	none
fluvoxamine	alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	none	D016666	none
fluvoxamine	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	4493	D016666	D005473
fluvoxamine	fluoxetine	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	4493	D016666	D005473
fluvoxamine	fluoxetine	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	4493	D016666	D005473
fluvoxamine	fluoxetine	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	4493	D016666	D005473
fluvoxamine	fluoxetine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	4493	D016666	D005473
fluvoxamine	fluoxetine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	4493	D016666	D005473
fluvoxamine	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	4493	D016666	D005473
fluvoxamine	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	4493	D016666	D005473
fluvoxamine	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	none	D016666	none
fluvoxamine	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	19	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine	lorazepam	20	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	6470	D016666	D008140
fluvoxamine	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	carbamazepine	20	21	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	2002	D016666	D002220
fluvoxamine	carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	2002	D016666	D002220
fluvoxamine	carbamazepine	23	21	false	none	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	2002	D016666	D002220
fluvoxamine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	37	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	37	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	1311214	D016666	D012701
fluvoxamine	serotonin	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	1311214	D016666	D012701
fluvoxamine	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		42355	448	D016666	D000431
fluvoxamine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	448	D016666	D000431
fluvoxamine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		42355	448	D016666	D000431
fluvoxamine	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	448	D016666	D000431
fluvoxamine	ethanol	20	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  		42355	448	D016666	D000431
fluvoxamine	tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		42355	10318	D016666	D013619
fluvoxamine	tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		42355	10318	D016666	D013619
fluvoxamine	tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		42355	10318	D016666	D013619
fluvoxamine	tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		42355	10318	D016666	D013619
fluvoxamine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	40	41	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	41	40	true	positive	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	10898	D016666	D014364
fluvoxamine	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	0	D016666	261563
fluvoxamine	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		42355	0	D016666	261563
fluvoxamine	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	0	D016666	261563
fluvoxamine	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	0	D016666	261563
fluvoxamine	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	0	D016666	261563
fluvoxamine	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		42355	0	D016666	261563
fluvoxamine	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	0	D016666	261563
fluvoxamine	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		42355	0	D016666	261563
fluvoxamine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine	Clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		42355	2626	D016666	D003024
fluvoxamine	Clozapine	23	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	2626	D016666	D003024
fluvoxamine	Clozapine	23	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  		42355	2626	D016666	D003024
fluvoxamine	Clozapine	24	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	2626	D016666	D003024
fluvoxamine	Clozapine	24	22	false	none	Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  Lithium: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.  Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  		42355	2626	D016666	D003024
fluvoxamine	benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	D001569
fluvoxamine	benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	D001569
fluvoxamine	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	D001569
fluvoxamine	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	D001569
fluvoxamine	benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	D001569
fluvoxamine	benzodiazepines	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	D001569
fluvoxamine	benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	D001569
fluvoxamine	benzodiazepines	12	14	false	none	If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  7.2 CNS Active Drugs    Antipsychotics: See WARNINGS AND PRECAUTIONS (5.3).  Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	D001569
fluvoxamine	Theophylline	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Theophylline	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Theophylline	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	Theophylline	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	Theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	Theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	none	D016666	none
fluvoxamine	Theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine	Theophylline	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	none	D016666	none
fluvoxamine	Theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine	Theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		42355	none	D016666	none
fluvoxamine	Theophylline	55	53	true	positive	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		42355	none	D016666	none
fluvoxamine	Theophylline	55	53	true	positive	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.  		42355	none	D016666	none
fluvoxamine	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	8331	D016666	D010868
fluvoxamine	Pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine	Pimozide	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	8331	D016666	D010868
fluvoxamine	dextromethorphan	4	6	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		42355	0	D016666	D003915
fluvoxamine	dextromethorphan	4	6	false	none	In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.  Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  		42355	0	D016666	D003915
fluvoxamine	dextromethorphan	7	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		42355	0	D016666	D003915
fluvoxamine	dextromethorphan	7	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  		42355	0	D016666	D003915
fluvoxamine	dextromethorphan	8	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		42355	0	D016666	D003915
fluvoxamine	dextromethorphan	8	6	false	none	Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.  While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.  This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.  		42355	0	D016666	D003915
fluvoxamine	Tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	57258	D016666	C023754
fluvoxamine	Tizanidine	35	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  		42355	57258	D016666	C023754
fluvoxamine	Propranolol	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Propranolol	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	none	D016666	none
fluvoxamine	Propranolol	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	Propranolol	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	none	D016666	none
fluvoxamine	Propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine	Propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine	Propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		42355	none	D016666	none
fluvoxamine	Propranolol	46	47	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  		42355	none	D016666	none
fluvoxamine	Propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine	Propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		42355	none	D016666	none
fluvoxamine	Propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	Propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	Propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	Propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	Propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine	Propranolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine	Propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	Propranolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	Propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	Propranolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	Propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	Propranolol	49	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	Propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	Propranolol	48	49	true	positive	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	Propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	Propranolol	48	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	Propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	Propranolol	48	47	true	positive	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	metoprolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	metoprolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		42355	none	D016666	none
fluvoxamine	metoprolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	metoprolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	metoprolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine	metoprolol	50	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine	metoprolol	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine	metoprolol	50	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  		42355	none	D016666	none
fluvoxamine	metoprolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	metoprolol	50	52	false	none	No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		42355	none	D016666	none
fluvoxamine	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	metoprolol	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	metoprolol	48	49	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		42355	none	D016666	none
fluvoxamine	metoprolol	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	metoprolol	48	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		42355	none	D016666	none
fluvoxamine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		42355	10502	D016666	D013881
fluvoxamine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		42355	10502	D016666	D013881
fluvoxamine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	10502	D016666	D013881
fluvoxamine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		42355	10502	D016666	D013881
fluvoxamine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine	triptan	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine	triptan	35	36	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		42355	none	D016666	none
fluvoxamine	triptan	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	triptan	35	37	false	none	Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		42355	none	D016666	none
fluvoxamine	triptan	37	38	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		42355	none	D016666	none
fluvoxamine	triptan	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	37	39	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		42355	none	D016666	none
fluvoxamine	triptan	37	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	triptan	37	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	triptan	37	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	triptan	37	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	triptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	none	D016666	none
fluvoxamine	triptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	none	D016666	none
fluvoxamine	triptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	none	D016666	none
fluvoxamine	triptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		42355	none	D016666	none
fluvoxamine	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		42355	none	D016666	none
fluvoxamine	omeprazole	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	4	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	7646	D016666	D009853
fluvoxamine	omeprazole	12	11	false	none	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see CONTRAINDICATIONS [4] and WARNINGS AND PRECAUTIONS [5]).  		42355	7646	D016666	D009853
Lorazepam	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		6470	596	D008140	D000525
Lorazepam	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		6470	596	D008140	D000525
Lorazepam	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		D008140	D008140
Lorazepam	lorazepam	17	18	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		D008140	D008140
Lorazepam	lorazepam	18	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		D008140	D008140
Lorazepam	lorazepam	18	18	true	negative	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  		D008140	D008140
Lorazepam	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
Lorazepam	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
Lorazepam	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
Lorazepam	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
pimozide	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	11289	D010868	D014859
pimozide	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	11289	D010868	D014859
pimozide	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	none
pimozide	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	none
pimozide	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	none
pimozide	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	none
pimozide	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	8183	D010868	D010672
pimozide	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	8183	D010868	D010672
pimozide	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	D001569
pimozide	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	D001569
pimozide	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	none
pimozide	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	none	D010868	none
pimozide	Pimozide	27	27	false	none	Pimozide: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).  		D010868	D010868
pimozide	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		D010868	D010868
pimozide	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	7646	D010868	D009853
pimozide	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	7646	D010868	D009853
warfarin	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	596	D014859	D000525
warfarin	alprazolam	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	596	D014859	D000525
warfarin	atenolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	atenolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	none
warfarin	p450	11	9	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	none
warfarin	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	none
warfarin	p450	11	10	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	none
warfarin	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	8183	D014859	D010672
warfarin	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	8183	D014859	D010672
warfarin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	D001569
warfarin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	D001569
warfarin	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	Theophylline	54	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	Theophylline	54	53	false	none	Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	none
warfarin	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	none	D014859	none
warfarin	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	8331	D014859	D010868
warfarin	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	8331	D014859	D010868
warfarin	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	57258	D014859	C023754
warfarin	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	57258	D014859	C023754
warfarin	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	none	D014859	none
warfarin	Propranolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	Propranolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	metoprolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	metoprolol	54	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  		11289	none	D014859	none
warfarin	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	7646	D014859	D009853
warfarin	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		11289	7646	D014859	D009853
warfarin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	7646	D014859	D009853
warfarin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		11289	7646	D014859	D009853
imipramine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	0	5691	D002997
imipramine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	0	5691	D002997
imipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	704	5691	704
imipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	704	5691	704
imipramine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		5691	1311214	5691	D012701
imipramine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		5691	1311214	5691	D012701
imipramine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	57258	5691	C023754
imipramine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	57258	5691	C023754
imipramine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	10502	5691	D013881
imipramine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		5691	10502	5691	D013881
imipramine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		5691	none	5691	none
imipramine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		5691	none	5691	none
Carbamazepine	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		D002220	D002220
Carbamazepine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		2002	448	D002220	D000431
Carbamazepine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		2002	448	D002220	D000431
Carbamazepine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		2002	2626	D002220	D003024
Carbamazepine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		2002	2626	D002220	D003024
clomipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		0	704	D002997	704
clomipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		0	704	D002997	704
clomipramine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		0	1311214	D002997	D012701
clomipramine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		0	1311214	D002997	D012701
clomipramine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		0	57258	D002997	C023754
clomipramine	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		0	57258	D002997	C023754
clomipramine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		0	10502	D002997	D013881
clomipramine	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		0	10502	D002997	D013881
clomipramine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		0	none	D002997	none
clomipramine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		0	none	D002997	none
alprazolam	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	p450	3	1	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	p450	3	2	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	p450	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	lorazepam	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	6470	D000525	D008140
alprazolam	lorazepam	15	17	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  		596	6470	D000525	D008140
alprazolam	benzodiazepines	15	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		596	none	D000525	D001569
alprazolam	benzodiazepines	15	14	false	none	Benzodiazepines: See WARNINGS AND PRECAUTIONS (5.8).  Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  		596	none	D000525	D001569
alprazolam	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	57258	D000525	C023754
alprazolam	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	57258	D000525	C023754
alprazolam	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	none	D000525	none
alprazolam	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	7646	D000525	D009853
alprazolam	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		596	7646	D000525	D009853
digoxin	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
digoxin	Tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
digoxin	alosetron	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	none	none	none
digoxin	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
digoxin	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
digoxin	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	10898	none	D014364
digoxin	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	0	none	261563
digoxin	Lotronex	43	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  		none	0	none	261563
atenolol	Theophylline	51	53	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
atenolol	Theophylline	52	53	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
atenolol	Propranolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	none	none	none
atenolol	Propranolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
atenolol	Propranolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
atenolol	metoprolol	51	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  No dosage adjustment is required for fluvoxamine maleate tablets.  Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  		none	none	none	none
atenolol	metoprolol	51	52	false	none	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.  Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
atenolol	metoprolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Tacrine	tacrine	31	31	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		D013619	D013619
Tacrine	tacrine	31	30	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		D013619	D013619
Tacrine	tacrine	30	31	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  		D013619	D013619
Tacrine	tacrine	30	30	true	positive	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  		D013619	D013619
Tacrine	Tizanidine	31	33	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		10318	57258	D013619	C023754
Tacrine	Tizanidine	31	33	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		10318	57258	D013619	C023754
Tacrine	Thioridazine	31	32	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
Tacrine	Thioridazine	31	32	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
Tacrine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
Tacrine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
amitriptyline	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		704	1311214	704	D012701
amitriptyline	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		704	1311214	704	D012701
amitriptyline	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		704	57258	704	C023754
amitriptyline	Tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		704	57258	704	C023754
amitriptyline	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		704	10502	704	D013881
amitriptyline	Thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  		704	10502	704	D013881
amitriptyline	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		704	none	704	none
amitriptyline	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		704	none	704	none
Tryptophan	alosetron	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	none	D014364	none
Tryptophan	alosetron	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	none	D014364	none
Tryptophan	alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	none	D014364	none
Tryptophan	alosetron	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	none	D014364	none
Tryptophan	fluoxetine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	4493	D014364	D005473
Tryptophan	fluoxetine	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	4493	D014364	D005473
Tryptophan	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		10898	4493	D014364	D005473
Tryptophan	fluoxetine	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		10898	4493	D014364	D005473
Tryptophan	serotonin	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	1311214	D014364	D012701
Tryptophan	serotonin	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	1311214	D014364	D012701
Tryptophan	tryptophan	40	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		D014364	D014364
Tryptophan	tryptophan	40	41	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		D014364	D014364
Tryptophan	tryptophan	41	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		D014364	D014364
Tryptophan	tryptophan	41	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		D014364	D014364
Tryptophan	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
Tryptophan	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
Tryptophan	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
Tryptophan	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
Tryptophan	triptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
Tryptophan	triptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
Tryptophan	triptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
Tryptophan	triptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
Tryptophan	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		10898	none	D014364	none
Tryptophan	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		10898	none	D014364	none
p450	phenytoin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
p450	phenytoin	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
p450	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
p450	phenytoin	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8183	none	D010672
p450	benzodiazepines	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
p450	benzodiazepines	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	D001569
p450	Theophylline	1	3	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
p450	Theophylline	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
p450	Theophylline	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
p450	Theophylline	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
p450	Theophylline	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	none	none
p450	Pimozide	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
p450	Pimozide	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
p450	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
p450	Pimozide	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
p450	Tizanidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
p450	Tizanidine	1	3	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
p450	Tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
p450	Tizanidine	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
p450	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
p450	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
p450	Propranolol	1	3	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
p450	Propranolol	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
p450	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
p450	omeprazole	1	3	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
p450	omeprazole	1	3	false	none	7 DRUG INTERACTIONS    7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes    Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.  The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
p450	omeprazole	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
p450	omeprazole	2	3	false	none	The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.  Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
p450	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
p450	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
p450	omeprazole	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
p450	omeprazole	9	11	false	none	Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).  The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
p450	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
p450	omeprazole	10	11	false	none	The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.  A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
phenytoin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	none	D010672	D001569
phenytoin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	none	D010672	D001569
phenytoin	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	none	D010672	none
phenytoin	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	none	D010672	none
phenytoin	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	8331	D010672	D010868
phenytoin	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	8331	D010672	D010868
phenytoin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	7646	D010672	D009853
phenytoin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8183	7646	D010672	D009853
alosetron	diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	none	none	none
alosetron	tryptophan	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	10898	none	D014364
alosetron	tryptophan	42	40	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	10898	none	D014364
alosetron	tryptophan	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	10898	none	D014364
alosetron	tryptophan	42	41	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	10898	none	D014364
alosetron	Lotronex	42	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	0	none	261563
alosetron	Lotronex	42	42	false	none	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		none	0	none	261563
fluoxetine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	1311214	D005473	D012701
fluoxetine	serotonin	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	1311214	D005473	D012701
fluoxetine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		4493	10898	D005473	D014364
fluoxetine	tryptophan	39	40	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		4493	10898	D005473	D014364
fluoxetine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		4493	10898	D005473	D014364
fluoxetine	tryptophan	39	41	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		4493	10898	D005473	D014364
fluoxetine	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	none	D005473	none
fluoxetine	triptan	39	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	none	D005473	none
fluoxetine	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	none	D005473	none
fluoxetine	triptan	39	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	none	D005473	none
fluoxetine	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	none	D005473	none
fluoxetine	triptan	39	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		4493	none	D005473	none
diltiazem	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	0	none	261563
diltiazem	Lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  		none	0	none	261563
diltiazem	Propranolol	44	46	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  		none	none	none	none
lorazepam	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
lorazepam	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
lorazepam	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
lorazepam	ethanol	18	19	false	none	On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  		6470	448	D008140	D000431
carbamazepine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		2002	448	D002220	D000431
carbamazepine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  		2002	448	D002220	D000431
carbamazepine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		2002	2626	D002220	D003024
carbamazepine	Clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).  		2002	2626	D002220	D003024
serotonin	tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		1311214	10898	D012701	D014364
serotonin	tryptophan	38	40	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		1311214	10898	D012701	D014364
serotonin	triptan	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	38	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		1311214	none	D012701	none
serotonin	triptan	38	39	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  		1311214	none	D012701	none
serotonin	triptan	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	38	36	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	38	37	false	none	If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	36	38	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	36	38	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  		1311214	none	D012701	none
serotonin	triptan	36	36	true	positive	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		1311214	none	D012701	none
serotonin	triptan	36	36	true	positive	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  		1311214	none	D012701	none
serotonin	triptan	36	37	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		1311214	none	D012701	none
serotonin	triptan	36	37	false	none	Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.  If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).  		1311214	none	D012701	none
tacrine	Tizanidine	31	33	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		10318	57258	D013619	C023754
tacrine	Tizanidine	31	33	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		10318	57258	D013619	C023754
tacrine	Thioridazine	31	32	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
tacrine	Thioridazine	31	32	false	none	Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
tacrine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
tacrine	Thioridazine	30	32	false	none	Tacrine: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.  Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.  Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  		10318	10502	D013619	D013881
tryptophan	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
tryptophan	Lotronex	40	42	false	none	Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
tryptophan	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
tryptophan	Lotronex	41	42	false	none	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex (alosetron) package insert.  		10898	0	D014364	261563
tryptophan	triptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
tryptophan	triptan	40	38	false	none	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.  If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
tryptophan	triptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
tryptophan	triptan	40	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  		10898	none	D014364	none
tryptophan	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		10898	none	D014364	none
tryptophan	triptan	41	39	false	none	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.  Tryptophan: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.  Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  		10898	none	D014364	none
benzodiazepines	Theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	none	D001569	none
benzodiazepines	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	D001569	D010868
benzodiazepines	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	D001569	D010868
benzodiazepines	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	D001569	D009853
benzodiazepines	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	D001569	D009853
Theophylline	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Theophylline	Pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	8331	none	D010868
Theophylline	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Theophylline	Tizanidine	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	57258	none	C023754
Theophylline	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	none	none	none
Theophylline	Propranolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Theophylline	metoprolol	53	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  Theophylline: See WARNINGS AND PRECAUTIONS (5.8).  		none	none	none	none
Theophylline	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Theophylline	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Theophylline	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
Theophylline	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		none	7646	none	D009853
Pimozide	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	7646	D010868	D009853
Pimozide	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.  		8331	7646	D010868	D009853
Tizanidine	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
Tizanidine	Propranolol	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	none	C023754	none
Tizanidine	Thioridazine	33	32	false	none	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10502	C023754	D013881
Tizanidine	Thioridazine	33	32	false	none	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  		57258	10502	C023754	D013881
Tizanidine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	7646	C023754	D009853
Tizanidine	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		57258	7646	C023754	D009853
Propranolol	metoprolol	49	49	false	none	If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Propranolol	metoprolol	49	48	false	none	One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Propranolol	metoprolol	52	52	false	none	Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.  		none	none	none	none
Propranolol	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	none	none	none
Propranolol	metoprolol	47	49	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.  		none	none	none	none
Propranolol	metoprolol	47	48	false	none	In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.  		none	none	none	none
Propranolol	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
Propranolol	omeprazole	3	3	false	none	Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).  		none	7646	none	D009853
